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Available online 16 June 2016Red blood cell (RBC) transfusions are essential for patientswith hematological disorders and bonemarrow failure
syndromes. Despite ABO matching, RBC transfusions can lead to production of alloantibodies against “minor”
blood group antigens. Non-ABO alloimmunization is a leading cause of transfusion-associated mortality in the
U.S. Despite its clinical importance, little is known about the immunological factors that promote
alloimmunization. Prior studies indicate that inﬂammatory conditions place patients at higher risk for
alloimmunization. Additionally, co-exposure to pro-inﬂammatory pathogen associated molecular patterns
(PAMPs) promotes alloimmunization in animal models, suggesting that RBC alloimmunization depends on in-
nate immune cell activation. However, the speciﬁc innate immune stimuli and sensors that induce a T cell-
dependent alloantibody response to transfused RBCs have not been identiﬁed. The NLRP3 inﬂammasome senses
chemically diverse PAMPs and damage associated molecular patterns (DAMPs), including extracellular ATP and
iron-containing heme. We hypothesized that activation of the NLRP3 inﬂammasome by endogenous DAMPs
from RBCs promotes the alloimmune response to a sterile RBC transfusion. Using geneticallymodiﬁedmice lack-
ing either NLRP3 or multiple downstream inﬂammasome response elements, we ruled out a role for the NLRP3
inﬂammasomeor any Caspase-1 or -11 dependent inﬂammasome in regulating RBC alloantibody production to a
model antigen.





Conventional dendritic cells (cDCs)
Red blood cell (RBC) storage1. Introduction
With 15million units transfused per year, red blood cell (RBC) trans-
fusion is the most common procedure performed in United States hos-
pitals (Pfuntner et al., 2013). Exposure to numerous foreign non-ABO
RBC antigens during transfusion can induce production of antibodies
to “minor” blood group antigens. As a result, approximately 3% of hospi-
talized patients (Fluit et al., 1990) and as many as 30–50% of patients
with sickle cell anemia (Vichinsky et al., 1990), develop alloantibodies
against these RBC antigens. Subsequent exposure to the offending RBCboratory Medicine, Yale School
, CT 06520., USA.
ity College of Physicians and
st 168th Street, P&S 14-434,
od),
. This is an open access article underantigen may result in potentially fatal hemolytic transfusion reactions,
which is a leading cause of transfusion-associated mortality (FDA,
2014). Although such reactions can be avoided by providing antigen-
negative RBC units, patients with rare or multiple RBC alloantibodies
may experience clinically signiﬁcant delays in transfusion, as laborato-
ries search for rare compatible blood products (Ryder et al., 2014). To
mitigate these adverse effects of alloimmunization, there is heightened
interest in identifying genetic and environmental factors that inﬂuence
the likelihood of alloantibody formation.
Multiple factors place patients at higher risk of alloimmunization.
These include genetic predisposition (e.g., HLA type), transfusion
burden, and co-incident inﬂammation (Higgins and Sloan, 2008;
Telen et al., 2015; Tatari-Calderone et al., 2009). Recipient inﬂammato-
ry status signiﬁcantly inﬂuences the frequency of alloimmunization;
an increased incidence of alloimmunization was reported in patients
with inﬂammatory bowel disease, autoimmune disease, febrile
transfusion reactions, and sickle cell-mediated acute chest syndromethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Yazer et al., 2009). Inmurine RBC transfusionmodels, exposure to pro-
inﬂammatory pathogen-associated molecular patterns (PAMPs) pro-
motes RBC alloimmune responses (Bao et al., 2009; Hendrickson et al.,
2006; Hendrickson et al., 2007; Elayeb et al., 2016). This suggests that
RBC alloimmunization, like most adaptive immune responses, de-
pends on innate immune cell activation to initiate antigen presenta-
tion and the requisite T cell priming signals (Calabro et al., 2016;
Krishnaswamy et al., 2013). However, the speciﬁc innate immune
stimuli provided by transfused RBCs that regulate a T cell-dependent
alloantibody response are not yet known. Recently, the species mis-
match of CD47 on transfused xenogeneic sheep RBCs was shown to in-
duce signiﬁcant inﬂammation in murine recipients (Yi et al., 2015).
However, in allogeneic RBC murine models, such a mismatch does not
exist and CD47 expression does not signiﬁcantly decrease on stored
murine RBCs (Gilson et al., 2009). Nonetheless, other alloantigen-
independent properties of donor RBCs, including length of refrigerated
storage, can inﬂuence post-transfusion inﬂammation and immunoge-
nicity (Ryder et al., 2014; Desai et al., 2015). During prolonged storage,
RBCs undergomorphologic transformations,metabolic changes and ox-
idative damage, leading to increased post-transfusion clearance and de-
creased RBC viability (Bennett-Guerrero et al., 2007; Tinmouth et al.,
2006). However, the cellular and molecular mechanisms, including
the recognition of stored RBC factors, underlying these observations
are poorly understood.
To examine the effect of RBC storage on inﬂammatory responses and
alloimmunization, we previously generated a mouse model of RBC
storage that approximates human RBC storage (Gilson et al., 2009).
Our studies demonstrated that transfusion of stored RBCs expressing
a chimeric protein containing hen egg lysozyme, ovalbumin, and the
human Duffy antigen (HOD), leads to accelerated RBC clearance, in-
creased inﬂammatory cytokine production, and enhanced alloantibody
production, compared to freshly collected RBCs (Hod et al., 2010;
Hendrickson et al., 2010). Transfusion of stored RBCs also resulted in el-
evated levels of tissue iron in the spleen and liver and production of cir-
culating non-transferrin bound iron (NTBI) in plasma. The inﬂammatory
response was attributed to phagocytosis of intact damaged stored RBCs
(i.e., extravascular hemolysis) (Hod et al., 2010). Although storage of
mouse and human RBCs may have differential effects, a prospective
study with human volunteers also demonstrated that transfusion of
stored RBCs led to elevated NTBI and extravascular hemolysis (Hod
et al., 2011). However, the mechanism by which innate immune cells
sensed iron or other RBC products was not investigated.
Innate non-immune and immune cells, including macrophages and
dendritic cells, utilize pattern recognition receptors (PRRs) to detect
PAMPs (Takeuchi and Akira, 2010). In addition, they can recognize
damage-associatedmolecular patterns (DAMPs),which derive from en-
dogenous molecules modiﬁed or released following cellular stress or
damage (Krishnaswamy et al., 2013). Many PRRs exist, including Toll-
like receptors (TLRs) and nucleotide-binding oligomerization domain
(NOD)-like receptors (NLRs), each sensing discrete types of stimuli.
For example, TLR4 recognizes the Gram-negative bacterial cell wall
component lipopolysaccharide (LPS) whereas NLR containing pyrin do-
main 3 (NLRP3) is activated by chemically diverse PAMPs and DAMPs
including protein aggregates, insoluble crystals, and bacterial pore-
forming toxins. Thus, identifying PRRs that promote storage-induced
alloimmunization can inform the identity of potential RBC DAMPs.
Many NLRs, including NLRP3, form a multi-molecular complex,
termed an ‘inﬂammasome’, that results in NLR oligomerization,
caspase-1 activation and enzymatic release of IL-1β and IL-18, which
contribute to T cell activity (Latz et al., 2013) (Liu et al., 2013). NLRP3
is activated by a wide array of DAMPs, including extracellular ATP
(Mariathasan et al., 2006), which is released from stored RBCs (Dern
et al., 1967). Hemozoin, a byproduct of heme catabolism in malarial in-
fection was also shown to activate NLRP3 (Shio et al., 2009). More re-
cently, Dutra et al. demonstrated that inﬂammation caused by iron-containing heme is critically regulated by NLRP3 and downstream
inﬂammasome components (Dutra et al., 2014). Therefore, we hypoth-
esized that activation of NLRP3 or other NLR inﬂammasomes by RBC-
associated DAMPs promotes the alloimmune response to sterile RBC
transfusion. Using genetically modiﬁed mice lacking either Nlrp3 or
multiple downstream common inﬂammasome response elements, we
tested whether the NLRP3 inﬂammasome was a sensor of stored RBCs.
Our data unambiguously excludes a critical role for the NLRP3
inﬂammasome or any caspase-1 or -11 dependent inﬂammasome in
alloimmunization to stored HOD RBCs.
2. Materials & Methods
2.1. Mice
C57BL/6 and UBC-GFP mice were purchased from Charles River and
Jackson Laboratory, respectively. HOD mice on the FVB background
were generated as previously described (Hendrickson et al., 2011;
Desmarets et al., 2009). Il1r−/−, Il18−/−, Casp1x11−/−, and Nlrp3−/−
mice were previously described (Sutterwala et al., 2006; Kuida et al.,
1995) (Labow et al., 1997). Il1r−/−, Il18−/− and Zbtb46-DTr mice
(Meredith et al., 2012) were purchased from The Jackson Laboratory.
All protocols used in this study were approved by the Yale Institutional
Animal Care and Use Committee.
2.2. RBC Transfusion
RBCs were collected from HOD and UBC-GFP transgenic or WT
C57BL/6 mice in 12% Citrate Phosphate Dextrose Adenine (CPDA-1) an-
ticoagulant (Desmarets et al., 2009) and leuko-reduced using amurine-
adapted Pall Acrodisc PSF 25mmWBCﬁlter or a Pall neonatalﬁlter with
Leukosorb Media prior to 4 °C storage for 7 or 14 days. Fresh RBCs were
not stored. Before transfusion, RBCs were washed with PBS. Following
centrifugation, packed RBCs were diluted 1:2 with sterile PBS. Diluted
RBCs (200 μL, the human equivalent of 1–2 RBC units) were transfused
i.v. into recipient mice. For inﬂammation-induced alloimmunization,
100 μg of polyinosinic:polycytidylic acid (poly(I:C), Amersham) were
injected i.p. 4 h prior to transfusion of fresh RBCs.
2.3. Detection of Alloantibodies
Serumwas collected three weeks after RBC transfusion. Levels of al-
loantibodies weremeasured by ﬂow cytometric cross-match or an anti-
HEL speciﬁc ELISA. For cross-match, serum was incubated with HOD+
RBCs or FVB RBCs, lacking the HOD antigen, for 30 min. RBCs were
then washed and stained with goat polyclonal anti-mouse Ig (BD
Pharmingen) for 30 min. Stained samples were washed and RBCs
were analyzed for the presence of anti-Ig by ﬂow cytometry. Anti-RBC
antibodies in ﬁgures indicate the level of anti-HOD antibodies, calculat-
ed by subtracting the mean ﬂuorescence intensity (MFI) of a serum
sample incubated with FVB RBCs from the MFI of a paired sample incu-
bated with HOD+ RBCs. For ELISA, anti-HEL speciﬁc IgG1 antibodies
were detected in sera (starting dilution 1:50) as described previously
(Hendrickson et al., 2007). Anti-IgG1 (clone A85-1) served as the detec-
tion antibody and HEL-speciﬁc IgG1 (clone 4B7) was used as the refer-
ence standard.
2.4. Inﬂammatory Cytokine Detection
Levels of inﬂammatory cytokines were measured as previously de-
scribed (Hod et al., 2010). Brieﬂy, serum cytokines, including
interleukin-6 (IL-6), tumor necrosis factor-α (TNF- α), monocyte
chemoattractant protein-1 (MCP-1), and keratinocyte-derived chemo-
kine (KC), were quantiﬁed using a Cytometric Bead Array Mouse Flex
Kit (BD Biosciences). Data were analyzed using FlowJo software (Tree
Star).
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Thioglycollate-elicited peritoneal macrophages were primed with
50 ng/mL LPS from E.coli serotype 0111:B4 (Invivogen) for 16–18 h
prior to stimulationwith either 500mg/mL Imject aluminumhydroxide
(Pierce) or 5 mM ATP for 8 h. For ATP-stimulated cells, the media was
changed at 20 min and all stimulants were replaced. IL-1β released
into culture supernatants was measured by ELISA. Antibody pairs for
ELISA were purchased from R&D Systems.
2.6. Flow Cytometry
Single cell suspensions of splenocytes were acquired with a
MACSQuant (Miltenyi) ﬂow cytometer and analyzed using FlowJo soft-
ware (Tree Star). The following antibodies were used for quantifying
cDCs and measuring cDC activation: TCRβ (H57-597) and CD11c
(N418) from eBiosciences; CD19 (RA3-6B2), MHC II (M5/114.15.2),
and CD86 (GL-1) from Biolegend. Zombie-NIR (Biolegend) was used
for exclusion of dead cells. For evaluating cDC activation, splenocytes
were processed 4 h following transfusion or i.v. injection of LPS.
2.7. Deletion of Conventional Dendritic Cells
To generate Zbtb46-DTr BM chimeric mice, wild type recipients
were irradiated with 2 doses of 650 rad 3 h apart. Two hours after the
second irradiation, 1 × 106 bone marrow cells from Zbtb46-DTr mice
were adoptively transferred via i.v. injection into recipientmice. For de-
pletion of cDCs, chimeric mice were treated with diphtheria toxin (DT,
Sigma-Aldrich), 7–10 weeks after bone marrow transplant. 60 ng of
DT/g of body weight was injected i.p. on Day 0 followed by a second
dose of 40 ng DT/g on Day 2. For alloimmunization experiments, HOD
RBCs were transfused on Day 3. DT dosage was titrated in Zbtb46-DTr
BM chimeric mice.
2.8. Statistical Analysis
Statistical signiﬁcance between two groups was determined by un-
paired t-test or MannWhitney U test for parametric and nonparametric
data, respectively. Signiﬁcance amongmultiple groups was determined
by one-way ANOVAwith Tukey post-test or Kruskal-Wallis with Dunns
post-test for parametric and nonparametric data, respectively. Normal-
ity was determined by the Kolmogorov-Smirnov test. Data were ana-
lyzed with GraphPad Prism software.
3. Results
3.1. Storage of HOD RBCs Promotes Inﬂammation and Alloimmunization
To examine the effect of RBC storage on post-transfusion inﬂamma-
tion and alloantibody responses, we transfused C57BL/6 wildtype
(WT) mice with leuko-reduced HOD RBCs that were freshly collected
or stored for 7 to 14 days in blood bankgrade citrate-phosphate dextrose
adenine solution (CPDA-1) at 4 °C. As previously reported (Hendrickson
et al., 2010), transfusion of 14-day stored, but not freshly collected RBCs,
resulted in a robust alloantibody response to the HOD antigen (Fig. 1a).
In accordancewith our prior study (Hod et al., 2010), transfusion of RBCs
stored for 14 days also induced inﬂammatory cytokine and chemokine
production (Fig. 1b, c). Storage for at least oneweekwas required to pro-
mote alloimmunization and inﬂammation, as RBC storage for 7 and
9 days, respectively, led to minimal responses (Fig. 1a, b). In our prior
study, infusion of RBC storage supernatant, RBC lysate, or RBC ghosts
did not induce inﬂammatory cytokine production. Accordingly, we ex-
amined whether transfusion of stored RBCs in the absence of accompa-
nying supernatant was also sufﬁcient to induce alloimmunization.
Transfusion of either washed or un-washed RBCs, stored for 14 days,
led to similar levels of alloantibody production as measured by HEL-speciﬁc ELISA (Fig. 1d), suggesting that the pro-inﬂammatory
factor(s) in stored RBCs is containedwithin the intact RBC. Thus, washed
14 day stored HOD RBCs were used for subsequent experiments.
Given that pre-treatment of recipient mice with pro-inﬂammatory
stimuli, including PAMPs, promotes alloimmune responses to trans-
fused RBCs (Bao et al., 2009; Hendrickson et al., 2006; Elayeb et al.,
2016), we compared the level of alloantibodies in mice transfused
with stored HOD RBCs to that induced by fresh RBCs in mice treated
with a model PAMP, polyinosinic:polycytidylic acid (poly(I:C)), 4 h
prior to transfusion. Both groups produced comparable levels of alloan-
tibodies (Fig. 1e), indicating that alterations that occur during RBC stor-
age make the cells pro-inﬂammatory and immunogenic. Given that
innate inﬂammatory responses can promote APC activation and adap-
tive immune responses (Iwasaki and Medzhitov, 2010), we next asked
whether stored RBCs promoted alloimmunization by activating innate
immune receptors on antigen presenting cells (APCs).
3.2. Stored HOD RBCs Activate cDCs Required for Alloimmunization
We previously demonstrated that inﬂammatory stimuli increase
RBC consumption by splenic dendritic cells (DCs) following transfusion
(Hendrickson et al., 2007). Conventional DCs (cDCs) are the primary
APCs that activate naïve CD4+ T cells (Meredith et al., 2012; Satpathy
et al., 2012). Thus, we examined the role of cDCs in the alloimmune re-
sponse to transfusion of stored HOD RBCs. By generating chimeric mice
with bone marrow from Zbtb46-DTR mice, which speciﬁcally express
the human diphtheria toxin receptor (DTR) under control of the zinc
ﬁnger transcription factor Zbtb46, cDCs can be selectively depleted
(Meredith et al., 2012). Administration of diphtheria toxin (DT) led to
a nearly complete depletion of cDCs in the spleen (Fig. 2a). Using this
system, we recently demonstrated (Calabro et al., 2016) that cDCs are
required for T cell-dependent alloantibody production in response to
transfusion of stored HOD RBCs (Fig. 2b). Using sensitive ELISA-based
methods, we conﬁrmed that cDC depletion by DT treatment prevented
alloantibody production to transfused stored HOD RBCs (Fig. 2c). Thus,
cDCs, which are activated by innate immune stimuli, are required for
alloimmunization to stored HOD RBCs. To determine if transfusion of
stored RBCs leads to cDC activation in vivo, wemeasured splenic DC sur-
face expression of MHC-II and CD86, which are upregulated during DC
maturation. Four hours after transfusion of stored HOD RBCs, both acti-
vation markers on cDCs were upregulated to levels comparable to LPS-
treated mice, which served as a positive control. Further, transfusion of
stored GFP-expressing RBCs and syngeneic C57BL/6 RBCs, which lack
the HOD antigen, also led to DC activation, indicating that the effect of
RBC storage on DC activation is independent of the RBC alloantigen
(Fig. 2d-e). However, the stored RBC-derived factors that activate cDCs
have not been identiﬁed.
3.3. The NLRP3 Inﬂammasome is not Required for Stored RBC-Induced In-
ﬂammation and Alloimmunization
DAMPs formed during RBC storage may activate cDCs by engaging
pattern recognition receptors, including NLRs. NLRP3, the best charac-
terized inﬂammasome-forming NLR, is activated by a wide variety of
DAMPs, including ATP (Mariathasan et al., 2006), which is released
from stored RBCs (Dern et al., 1967). Previous studies have shown
that transfusion of stored HOD RBCs results in elevated levels of intra-
cellular iron in APCs and NTBI in plasma (Hod et al., 2010, 2011).
Heme-containing iron and other factors produced by stored RBCs have
been shown to activate the NLRP3 inﬂammasome (Mariathasan et al.,
2006; Dutra et al., 2014). As shown in Fig. 3a, following recognition of
discrete inﬂammatory stimuli, NLRP3 oligomerizes and recruits the
adapter, apoptosis-associated speck-like protein containing a CARD
(ASC). This complex activates caspase-1, which leads to activation and
secretion of IL-1β and IL-18 cytokines. To determine whether the
NLRP3 inﬂammasome is required for stored RBC-induced inﬂammation
Fig. 1. Storage of HOD RBCs profoundly enhances transfusion-induced alloimmunization.WT C57BL/6 mice were transfused i.v. with stored or freshly collected HOD RBCs. a) Flow
cytometric cross-match of anti-HOD RBC antibodies measured in sera of naïve untransfused mice and mice transfused with RBCs stored for 7 or 14 days, or freshly collected. Anti-RBC
antibodies were calculated by subtracting the MFI of a serum sample incubated with RBCs lacking the HOD antigen from the MFI of a paired sample incubated with HOD+ RBCs. n =
3–8 mice/group; results are representative of 3 independent experiments. b) Monocyte chemoattractant protein-1 (MCP-1) in serum 2–4 h following transfusion of RBCs stored for
indicated times prior to transfusion measured by cytometric bead array. c) Inﬂammatory cytokines in serum as in (b) from mice transfused with RBCs stored for 14 days (+RBCs) or
not transfused (−RBCs); Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), MCP-1, and keratinocyte-derived chemokine (KC). n = 2–7 mice/group; results are representative of 4
independent experiments. d) Anti-HEL antibodies, quantiﬁed by ELISA, in sera diluted 1:50 from mice transfused with RBCs stored for 14 days and either washed with PBS or
unwashed prior to transfusion. Unwashed samples contain storage supernatant. n = 5 mice/group; results are representative of 2 independent experiments. NS, not signiﬁcant. e)
Serum anti-HEL antibodies in mice that received stored (14 day-old), freshly collected (Fresh), or Fresh RBCs 4 h following i.p. administration of 100 μg poly(I:C) (Fresh + PIC). Error
bars indicate standard deviation. n = 5 mice/group; results are representative of 2–3 independent experiments. **p b 0.01; ***p b 0.001; ****p b 0.0001.
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tiple inﬂammatory cytokines and chemokines (as in Fig. 1) and anti-
HODRBC alloantibodies inNlrp3−/− andWTmice. Therewere no signif-
icant differences in levels of IL-6, TNFα, MCP1 or KC produced by
Nlrp3−/− as compared to WT mice (Fig. 3b). Additionally, Nlrp3 deﬁ-
ciency did not impair HOD-speciﬁc alloantibody production (Fig. 3c).
Yet primary macrophages from Nlrp3−/− and Casp1x11−/−mice failed
to respond, as measured by IL-1β secretion, to known Nlrp3
inﬂammasome activators including aluminum hydroxide and ATP
(Fig. 3d) (Mariathasan et al., 2006; Eisenbarth et al., 2008; Li et al.,
2008). Thus, NLRP3 does not critically regulate the inﬂammatory or al-
loantibody response to transfused stored HOD RBCs.3.4. NLR Inﬂammasomes Do Not Regulate Inﬂammation and
Alloimmunization Induced by Stored RBCs
Although NLRP3 is the best characterized inﬂammasome-forming
NLR, numerous other NLRs, including NLRC4, NLRP1 and NLRP6, also
form inﬂammasomes that activate caspase-1 and, under certain circum-
stances, also caspase-11 (Liu et al., 2013) (Afonina et al., 2015). Thus, to
determine the potential role of other inﬂammasome-forming NLRs in
storage-induced inﬂammation and alloimmunization, we utilized
caspase-1 and caspase-11 double deﬁcient mice (Casp1x11−/−) and
mice unable to respond with inﬂammasome-dependent cytokines, Il-
1r−/− and Il-18−/− mice (Il1rxIl18−/−). These latter double deﬁcient
Fig. 2. Stored RBCs activate splenic DCs. (a–c) Chimeric mice were generated with bonemarrow from Zbtb46-DTR mice, as described in theMethods, and treated with diphtheria toxin
prior to transfusionwith HOD RBCs stored for 14 days. a) Representative ﬂow cytometric analysis of CD11c+MHC-II+ cDCs in spleens of mice treatedwith (+) orwithout (−) diphtheria
toxin (DT). Dot plotswere gated on live TCRβ−CD19−non-lymphocytes. Numbers onplots indicate thepercentage of gated cellswithin the indicatedgate. b, c) Anti-RBC antibodies in sera
of mice treated with or without DT prior to stored HOD RBC transfusion, quantiﬁed by ﬂow cytometric cross-match (b) or ELISA (c) as in Fig. 1. n = 6–10 mice/group; results are
representative of 5 independent experiments. ****p b 0.0001; **p b 0.01. d–e) Expression of activation markers, CD86 and MHC-II, on spleen cDCs (gated as in a) from naïve mice
(shaded) or mice injected i.v. 4 h prior (open histogram) with (d) LPS, stored HOD RBCs, stored GFP-expressing RBCs or (e) stored WT C57BL/6 RBCs. 1 representative mouse from 2
mice/group from 3 independent experiments.
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both IL-1α and IL-1β signal via IL-1R, the IL-1R−/− mice abrogate
signaling to both cytokines. First, Casp1x11−/−mice were transfused
with stored HOD RBCs and serum pro-inﬂammatory cytokine/che-
mokine and alloantibody levels were assessed. As shown in Fig. 4a
and b, loss of caspase-1 and caspase-11 did not signiﬁcantly affect
IL-6, TNFα, MCP1 or KC serum levels or alloantibody production as
compared to WT mice. Second, Il1rxIl18−/− mice were transfusedwith stored HOD RBCs and alloantibodies were measured to assess
the potential impact of loss of inﬂammasome-dependent cytokines
on the alloimmune response. Compared to WT controls, Il1rxIl18−/−
mice, as well as Nlrp3−/− and Casp1x11−/− mice, produced equiva-
lent levels of alloantibodies to stored HOD RBCs after transfusion
(Fig. 4c). Thus, NLR-inﬂammasomes are not required for the acute
inﬂammatory response or the adaptive alloimmune response to
transfused stored RBCs.
Fig. 3. Nlrp3 is not required for RBC alloimmunization. a) Theoretical model of NLRP3 inﬂammasome activation by stored RBC DAMPs in a dendritic cell. Following recognition of
possible inﬂammatory stimuli, such as ATP, iron or heme, NLRP3 oligomerizes, recruits ASC and caspase-1, which enzymatically cleaves pro-cytokines, resulting in secretion of active
IL-18 and IL-1β. MHC-II is upregulated following activation and presents RBC antigens to antigen-speciﬁc T cells. ASC, apoptosis-associated speck-like protein containing a CARD. b,c)
Inﬂammatory cytokines (b) and anti-RBC alloantibodies (c) in sera of indicated mice following transfusion with stored HOD RBCs, quantiﬁed as in Fig. 1. n = 3–5 mice/group. Dotted
line in (b) indicates level of serum cytokines in naïve mice from the same experiment. Data are representative of 5 independent experiments. d) IL-1β, measured by ELISA, in
supernatants of ex vivo cultured thioglycollate-elicited peritoneal macrophages from indicated mice primed with 50 ng/mL LPS for 16–18 h prior to stimulation with either 500 ng/mL
alum or 5 mM ATP for 8 h. Dotted line indicates level of detection of ELISA. Mean with s.d. from triplicate wells. Representative data from 3 independent experiments. NS, not
signiﬁcant; *p b 0.05; ****p b 0.0001.
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Identifying patients with an elevated risk of forming alloantibodies
to non-ABO RBC antigens could lead to directed preventative measures,
including antigen matching, or therapeutic interventions that mitigate
the alloimmune response (Hendrickson et al., 2014). In light of theclinical signiﬁcance of RBC alloimmunization, progress in this area
could substantially decrease associated adverse events, includinghemo-
lytic transfusion reactions and general morbidity and mortality (Nickel
et al., 2016). However, to develop criteria for biomarkers or cytokine
proﬁles that have predictive value, mechanisms underlying the
alloantibody-forming adaptive immune responsesmust be determined.
Fig. 4. Inﬂammasomes are not required for RBC alloimmunization. a) Inﬂammatory cytokines in sera ofWT and Caspase-1xCaspase-11 (Casp1x11−/−) double deﬁcientmice quantiﬁed
by cytometric bead array 2 h after transfusionwith HOD RBCs stored for 14 days. Dotted line indicates level of serum cytokines in naïvemice from the same experiment. b) Anti-HOD RBC
alloantibodies in sera were quantiﬁed by cytometric cross-match, as in Fig. 1, from WT and Casp1x11−/− mice 21 days after HOD RBC transfusion. Naïve mice did not receive RBC
transfusion. n = 3–9 mice/group; results are representative of 6 independent experiments. c) Anti-HOD RBC alloantibodies in sera fromWT, Nlrp3−/−, Casp1x11−/− and IL1R and IL-
18 double deﬁcient mice 21 days after transfusion with stored HOD RBCs. No signiﬁcant differences determined by one-way ANOVA. n = 2–8 mice/group; results are representative of
3 independent experiments. *p b 0.05; NS, not signiﬁcant.
83D.R. Gibb et al. / EBioMedicine 9 (2016) 77–86Using the mouse transfusion model of HOD RBCs, we and others
have shown that refrigerated RBC storage increases the inﬂammatory
(Hod et al., 2010) and alloantibody (Hendrickson et al., 2010) responses
of recipients. In parallel, a clinical study has shown that the age of trans-
fused RBCs is associated with alloimmunization in patients with sicklecell disease (Desai et al., 2015). The pronounced increase in alloanti-
bodies in our studies occurred following 7–14 days of murine RBC stor-
age. Signiﬁcant differences have been noted in the risk of alloantibody
formation between 7 and 35 days of human RBC storage (Desai et al.,
2015). In addition, a recent study by Veale et al. found that the
84 D.R. Gibb et al. / EBioMedicine 9 (2016) 77–86susceptibility of stored human RBCs to in vitro erythrophagocytosis in-
creased signiﬁcantly with storage duration (Veale et al., 2014). We con-
clude that DAMPs are formed and contained within intact murine RBCs
during the second week of storage, and hypothesize that DAMPs may
also be formed in human RBCs the week prior to outdate. This ﬁnding
is supported by a prior study demonstrating that intact HOD RBCs, but
not RBC lysate or RBC ghosts generated from stored cells, induce inﬂam-
matory cytokine production following transfusion (Hod et al., 2010).
Further studies addressing metabolic changes within intact stored
RBCs could potentially identify immunogenic DAMPs.
Treatment of recipients with the pro-inﬂammatory PAMP, poly(I:C),
prior to fresh HOD RBC transfusion resulted in alloantibody production
comparable to the response to stored RBCs (Fig. 1e). It should be noted
that this study did not directly address whether the demonstrated pro-
inﬂammatory cytokine response to transfused stored HOD RBCs was
necessary for alloimmunization. However, multiple studies in mice
and humans have reported associations between inﬂammatory states
and alloimmunization (Ramsey and Smietana, 1995; Fasano et al.,
2015; Papay et al., 2012; Yazer et al., 2009; Hendrickson et al., 2006;
Ryder et al., 2015). Additionally, it is ﬁrmly accepted that innate inﬂam-
matory responses can promote APC activation and adaptive immune re-
sponses (Iwasaki and Medzhitov, 2010). Although many APC cell types
consume transfused RBCs in the spleen (Richards et al., 2016), we have
demonstrated that splenic cDCs critically regulate the alloantibody re-
sponse to stored HOD RBCs in a T cell-dependent manner (Calabro
et al., 2016). We also observed that stored RBCs induce cDC activation,
independent of HOD expression. However, it is not clear whether stored
RBC DAMPs are directly recognized by cDCs. PRR activation in CD11b+-
Ly6C+F4/80+ macrophages, shown to consume stored RBCs (Calabro
et al., 2016), may instead cause production of pro-inﬂammatory cyto-
kines that activate cDCs and promote cDC phagocytic activity. Such an
indirect mechanism is supported by a prior study reporting that
clodronate-induced macrophage depletion abrogates MCP-1 and KC
production following transfusion of stored RBCs (Wojczyk et al.,
2014). Regardless, these ﬁndings suggest that cDC activation may criti-
cally regulate the alloimmune response. Yet, the initiation process for
cDC activation has not been deﬁned.
To address this challenge, we took advantage of the discrete na-
ture of PRR:DAMP interactions. Thus, identifying a PRR pathway
that regulates alloimmunization will greatly narrow the search for
relevant immunomodulatory DAMPs in stored RBCs. It also has the
potential to identify downstream cytokine proﬁles associated with
alloimmunization. Although numerous PRRs could be tested, NLRP3
and other inﬂammasome-forming NLRs were excellent candidates.
NLRP3 is activated by numerous DAMPs, including protein aggre-
gates, insoluble crystals, and products of cell death (Krishnaswamy
et al., 2013) (Guo et al., 2015; Storek and Monack, 2015). With
regards to potential RBC DAMPs, NLRP3 inﬂammasomes are activat-
ed by ATP (Mariathasan et al., 2006), which is released from dam-
aged RBCs (Dern et al., 1967), and iron-containing heme (Dutra
et al., 2014), which can be produced by intracellular catabolism of
phagocytosed RBCs (Hod et al., 2010). In addition, reactive oxygen
species, which prime NLRP3 activation (Juliana et al., 2012), were
implicated in stored HOD RBC-induced inﬂammation, which was re-
duced by anti-oxidant treatment (Hod et al., 2010). Nonetheless, the
lack of NLRP3 or associated caspase-1 or caspase-11 had no signiﬁ-
cant effect on stored RBC-induced inﬂammatory and alloimmune re-
sponses. This ﬁnding was supported by alloimmune responses of
Il1rxIl18−/−mice that were comparable toWT responses. We cannot
exclude the possibility that NLR-forming inﬂammasomes could per-
formmore signiﬁcant roles in response to storage of RBCs expressing
other antigens, not tested in this study. We believe this possibility is
unlikely given our ﬁndings that the nature of the alloantigen on the
stored RBCs did not impact DC activation.
Although not examined in this study, other PRRs, including TLRs and
Rig-I-like receptors (RLRs), may regulate responses to stored RBCs. Eventhough TLRs and RLRs primarily recognize foreign PAMPs, they can also
recognize certain DAMPs, including self-nucleic acids and intracellular
molecules released during cell death (Piccinini and Midwood, 2010).
Red blood cells are not nucleated, yet the washed leuko-reduced RBC
preparations contain reticulocytes, platelets, and a low level of leuko-
cytes (Ryder et al., 2014) that may release TLR ligands during storage.
Future studies examining inﬂammatory and adaptive immune re-
sponses of various PRR-deﬁcient mice to different RBC preparations
may lead to progress in identifying DAMPs associated with
alloimmunization. Indeed, identiﬁcation of a potential DAMP endoge-
nous to RBCs themselves or to the RBC product preparation could rede-
ﬁne transfusion practices.
Of note, it is not known whether the ﬁndings observed in the HOD
model will translate to murine RBCs expressing other antigens, or to
humans. Human studies investigating the role of RBC storage duration
on alloimmunization and other adverse effects have reported varied
outcomes (Dinardo et al., 2015; Yazer and Triulzi, 2010; Zalpuri et al.,
2013; Desai et al., 2015; Koch et al., 2008; Offner et al., 2002; Purdy
et al., 1997; Vandromme et al., 2009; Weinberg et al., 2008; Zallen
et al., 1999; Fergusson et al., 2012; Lacroix et al., 2015; Steiner et al.,
2015) Future studies are needed in animals and humans, to determine
which immune pathways are common or divergent.
5. Conclusion
In conclusion, this study utilized a mouse model of stored HOD RBC
transfusion to investigate underlying mechanisms of inﬂammation-
induced alloimmunization. Transfusion of stored RBCs induced pro-
inﬂammatory cytokine production and pronounced alloantibody re-
sponses. In addition, storage of RBCs resulted in activation of cDCs,
which are required to promote the alloimmune response. Finally, al-
though inﬂammasome-forming NLRs were excellent candidates for
responding to DAMPs formed by stored RBCs, this study rules out a crit-
ical role for NLR inﬂammasomes in regulating the inﬂammatory and
alloimmune responses to stored HOD RBCs.
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